Model informed dosing of hydroxycholoroquine in COVID-19 patients: Learnings from the recent experience, remaining uncertainties and gaps.
Pauline ThémansNicolas DaubyLoïc SchrooyenFaustine LeboutMarc DelforgeRakan NasreddineAgnès LiboisMarie-Christine PayenDéborah KonopnickiFrancoise WuillaumeCecile LescrainierVeerle VerlindenJean-Michel DognéJamila HamdaniFlora T MusuambaPublished in: British journal of clinical pharmacology (2020)
Our results were clear, indicating the unmet need for characterization of target PK exposures to inform HCQ dosing optimization in COVID-19. Dosing optimization for HCQ in COVID-19 is still an unmet need. Efforts in this sense are a prerequisite for best benefit/risk balance.